Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer
Published on 24 October 2026
Dr Randy Sweis speaks to ecancer about the phase Ib TROPHY-U-01 Cohort 7 study.
The study evaluates sacituzumab govitecan combined with enfortumab vedotin and the PD-1 inhibitor zimberelimab in patients with previously untreated metastatic urothelial cancer.
He highlights that among 18 efficacy-evaluable patients, the combination achieved an objective response rate of 83%, including three complete responses.
Treatment-related toxicities were manageable, with no evidence of additive toxicity beyond the expected profiles of the individual drugs.
Dr Sweis says that the findings support further investigation of this combination as a potential first-line treatment approach for metastatic urothelial cancer.